메뉴 건너뛰기




Volumn 42, Issue 1, 2013, Pages 101-108

Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma

Author keywords

Hepatocellular carcinoma; Sorafenib; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BETA CATENIN; CISPLATIN; DOXORUBICIN; FLICE INHIBITORY PROTEIN; FLUOROURACIL; LUCIFERASE; PROTEIN BCL XL; SORAFENIB; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WNT PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

EID: 84873631084     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1676     Document Type: Article
Times cited : (14)

References (38)
  • 1
    • 0036237822 scopus 로고    scopus 로고
    • Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma
    • DOI 10.1053/jhep.2002.33156
    • Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002. (Pubitemid 34454013)
    • (2002) Hepatology , vol.35 , Issue.5 , pp. 1164-1171
    • Lo, C.-M.1    Ngan, H.2    Tso, W.-K.3    Liu, C.-L.4    Lam, C.-M.5    Poon, R.T.-P.6    Fan, S.-T.7    Wong, J.8
  • 2
    • 0037308133 scopus 로고    scopus 로고
    • Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
    • DOI 10.1053/jhep.2003.50047
    • Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442, 2003. (Pubitemid 36152543)
    • (2003) Hepatology , vol.37 , Issue.2 , pp. 429-442
    • Llovet, J.M.1    Bruix, J.2
  • 3
    • 0033503797 scopus 로고    scopus 로고
    • Intrahepatic recurrence after curative resection of hepatocellular carcinoma: Long-term results of treatment and prognostic factors
    • DOI 10.1097/00000658-199902000-00009
    • Poon RT, Fan ST, Lo CM, Liu CL and Wong J: Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229: 216-222, 1999. (Pubitemid 30191795)
    • (1999) Annals of Surgery , vol.229 , Issue.2 , pp. 216-222
    • Poon, R.T.-P.1    Fan, S.-T.2    Lo, C.-M.3    Liu, C.-L.4    Wong, J.5
  • 4
    • 0642338431 scopus 로고    scopus 로고
    • Selection Criteria for Repeat Hepatectomy in Patients with Recurrent Hepatocellular Carcinoma
    • DOI 10.1097/01.sla.0000094549.11754.e6
    • Minagawa M, Makuuchi M, Takayama T and Kokudo N: Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238: 703-710, 2003. (Pubitemid 38182262)
    • (2003) Annals of Surgery , vol.238 , Issue.5 , pp. 703-710
    • Minagawa, M.1    Makuuchi, M.2    Takayama, T.3    Kokudo, N.4
  • 5
    • 78649709091 scopus 로고    scopus 로고
    • Liver transplantation for hepatocellular carcinoma: The Kyoto experience
    • Takada Y and Uemoto S: Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci 17: 527-532, 2010.
    • (2010) J Hepatobiliary Pancreat Sci , vol.17 , pp. 527-532
    • Takada, Y.1    Uemoto, S.2
  • 6
    • 77957603190 scopus 로고    scopus 로고
    • Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting
    • Thomas MB, Jaffe D, Choti MM, et al: Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28: 3994-4005, 2010.
    • (2010) J Clin Oncol , vol.28 , pp. 3994-4005
    • Thomas, M.B.1    Jaffe, D.2    Choti, M.M.3
  • 7
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 8
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
    • Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3
  • 11
    • 59849120213 scopus 로고    scopus 로고
    • Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]
    • Hoffmann K, Glimm H, Radeleff B, et al: Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 8: 349, 2008.
    • (2008) BMC Cancer , vol.8 , pp. 349
    • Hoffmann, K.1    Glimm, H.2    Radeleff, B.3
  • 12
    • 78349298645 scopus 로고    scopus 로고
    • Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial
    • Abou-Alfa GK, Johnson P, Knox JJ, et al: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304: 2154-2160, 2010.
    • (2010) JAMA , vol.304 , pp. 2154-2160
    • Abou-Alfa, G.K.1    Johnson, P.2    Knox, J.J.3
  • 13
    • 77953124105 scopus 로고    scopus 로고
    • Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
    • Hsu CH, Shen YC, Lin ZZ, et al: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53: 126-131, 2010.
    • (2010) J Hepatol , vol.53 , pp. 126-131
    • Hsu, C.H.1    Shen, Y.C.2    Lin, Z.Z.3
  • 14
    • 80054722090 scopus 로고    scopus 로고
    • Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma
    • Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N and Geschwind JF: Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29: 3960-3967, 2011.
    • (2011) J Clin Oncol , vol.29 , pp. 3960-3967
    • Pawlik, T.M.1    Reyes, D.K.2    Cosgrove, D.3    Kamel, I.R.4    Bhagat, N.5    Geschwind, J.F.6
  • 15
    • 79959373568 scopus 로고    scopus 로고
    • The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma
    • Cabrera R, Pannu DS, Caridi J, et al: The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 34: 205-213, 2011.
    • (2011) Aliment Pharmacol Ther , vol.34 , pp. 205-213
    • Cabrera, R.1    Pannu, D.S.2    Caridi, J.3
  • 16
    • 84859750869 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
    • Petrini I, Lencioni M, Ricasoli M, et al: Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 69: 773-780, 2012.
    • (2012) Cancer Chemother Pharmacol , vol.69 , pp. 773-780
    • Petrini, I.1    Lencioni, M.2    Ricasoli, M.3
  • 17
    • 0033839749 scopus 로고    scopus 로고
    • Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines
    • Yamanaka T, Shiraki K, Sugimoto K, et al: Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32: 482-490, 2000.
    • (2000) Hepatology , vol.32 , pp. 482-490
    • Yamanaka, T.1    Shiraki, K.2    Sugimoto, K.3
  • 20
    • 75449102003 scopus 로고    scopus 로고
    • TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies
    • Koehler BC, Urbanik T, Vick B, et al: TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 15: 5924-5935, 2009.
    • (2009) World J Gastroenterol , vol.15 , pp. 5924-5935
    • Koehler, B.C.1    Urbanik, T.2    Vick, B.3
  • 21
    • 84984559474 scopus 로고    scopus 로고
    • Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
    • Chen KF, Tai WT, Liu TH, et al: Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16: 5189-5199, 2010.
    • (2010) Clin Cancer Res , vol.16 , pp. 5189-5199
    • Chen, K.F.1    Tai, W.T.2    Liu, T.H.3
  • 24
    • 3042674026 scopus 로고    scopus 로고
    • Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma
    • Shiraki K, Sugimoto K, Yamanaka Y, et al: Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int J Mol Med 12: 705-708, 2003.
    • (2003) Int J Mol Med , vol.12 , pp. 705-708
    • Shiraki, K.1    Sugimoto, K.2    Yamanaka, Y.3
  • 25
    • 27744497446 scopus 로고    scopus 로고
    • Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death
    • Yamaguchi Y, Shiraki K, Fuke H, et al: Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep 14: 1311-1316, 2005.
    • (2005) Oncol Rep , vol.14 , pp. 1311-1316
    • Yamaguchi, Y.1    Shiraki, K.2    Fuke, H.3
  • 26
    • 79955979815 scopus 로고    scopus 로고
    • Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy
    • Kim JW, Lee JO, Han SW, et al: Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. Am J Clin Oncol 34: 125-129, 2010.
    • (2010) Am J Clin Oncol , vol.34 , pp. 125-129
    • Kim, J.W.1    Lee, J.O.2    Han, S.W.3
  • 27
    • 33747830764 scopus 로고    scopus 로고
    • Hepatocellular carcinoma pathogenesis: From genes to environment
    • DOI 10.1038/nrc1934, PII NRC1934
    • Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006. (Pubitemid 44286000)
    • (2006) Nature Reviews Cancer , vol.6 , Issue.9 , pp. 674-687
    • Farazi, P.A.1    DePinho, R.A.2
  • 28
    • 54449083925 scopus 로고    scopus 로고
    • Molecular targeted therapies in hepatocellular carcinoma
    • Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
    • (2008) Hepatology , vol.48 , pp. 1312-1327
    • Llovet, J.M.1    Bruix, J.2
  • 29
    • 34547819299 scopus 로고    scopus 로고
    • The promise of TRAIL - Potential and risks of a novel anticancer therapy
    • DOI 10.1007/s00109-007-0194-1
    • Koschny R, Walczak H and Ganten TM: The promise of TRAIL potential and risks of a novel anticancer therapy. J Mol Med (Berl) 85: 923-935, 2007. (Pubitemid 47282789)
    • (2007) Journal of Molecular Medicine , vol.85 , Issue.9 , pp. 923-935
    • Koschny, R.1    Walczak, H.2    Ganten, T.M.3
  • 30
    • 52649109068 scopus 로고    scopus 로고
    • The TRAIL apoptotic pathway in cancer onset, progression and therapy
    • Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798, 2008.
    • (2008) Nat Rev Cancer , vol.8 , pp. 782-798
    • Johnstone, R.W.1    Frew, A.J.2    Smyth, M.J.3
  • 31
    • 77949686312 scopus 로고    scopus 로고
    • Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells
    • Huang S and Sinicrope FA: Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 9: 742-750, 2010.
    • (2010) Mol Cancer Ther , vol.9 , pp. 742-750
    • Huang, S.1    Sinicrope, F.A.2
  • 32
    • 76249092117 scopus 로고    scopus 로고
    • The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
    • Llobet D, Eritja N, Yeramian A, et al: The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 46: 836-850, 2010.
    • (2010) Eur J Cancer , vol.46 , pp. 836-850
    • Llobet, D.1    Eritja, N.2    Yeramian, A.3
  • 33
    • 13844267552 scopus 로고    scopus 로고
    • The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines
    • DOI 10.1097/00001813-200502000-00003
    • Heim M, Scharifi M, Zisowsky J, et al: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16: 129-136, 2005. (Pubitemid 40250607)
    • (2005) Anti-Cancer Drugs , vol.16 , Issue.2 , pp. 129-136
    • Heim, M.1    Scharifi, M.2    Zisowsky, J.3    Jaehde, U.4    Voliotis, D.5    Seeber, S.6    Strumberg, D.7
  • 34
    • 33744791463 scopus 로고    scopus 로고
    • Wnt signaling: Is the party in the nucleus?
    • DOI 10.1101/gad.1424006
    • Willert K and Jones KA: Wnt signaling: is the party in the nucleus? Genes Dev 20: 1394-1404, 2006. (Pubitemid 43830647)
    • (2006) Genes and Development , vol.20 , Issue.11 , pp. 1394-1404
    • Willert, K.1    Jones, K.A.2
  • 35
    • 33947217823 scopus 로고    scopus 로고
    • Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia
    • DOI 10.1038/ncb1534, PII NCB1534
    • Kaidi A, Williams AC and Paraskeva C: Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9: 210-217, 2007. (Pubitemid 46420864)
    • (2007) Nature Cell Biology , vol.9 , Issue.2 , pp. 210-217
    • Kaidi, A.1    Williams, A.C.2    Paraskeva, C.3
  • 36
    • 48549098557 scopus 로고    scopus 로고
    • Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin
    • Lim JH, Chun YS and Park JW: Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin. Cancer Res 68: 5177-5184, 2008.
    • (2008) Cancer Res , vol.68 , pp. 5177-5184
    • Lim, J.H.1    Chun, Y.S.2    Park, J.W.3
  • 37
    • 77957584397 scopus 로고    scopus 로고
    • O2 regulates stem cells through Wnt/beta-catenin signalling
    • Mazumdar J, O'Brien WT, Johnson RS, et al: O2 regulates stem cells through Wnt/beta-catenin signalling. Nat Cell Biol 12: 1007-1013, 2010.
    • (2010) Nat Cell Biol , vol.12 , pp. 1007-1013
    • Mazumdar, J.1    O'Brien, W.T.2    Johnson, R.S.3
  • 38
    • 80051481674 scopus 로고    scopus 로고
    • Wnt-beta-catenin signaling protects against hepatic ischemia and reperfusion injury in mice
    • Lehwald N, Tao GZ, Jang KY, Sorkin M, Knoefel WT and Sylvester KG: Wnt-beta-catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterology 141: 707-718, 2011.
    • (2011) Gastroenterology , vol.141 , pp. 707-718
    • Lehwald, N.1    Tao, G.Z.2    Jang, K.Y.3    Sorkin, M.4    Knoefel, W.T.5    Sylvester, K.G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.